Patents by Inventor Jocelyn Laporte

Jocelyn Laporte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DYNAMIN 2 INHIBITOR FOR THE TREATMENT OF CENTRONUCLEAR MYOPATHIES
    Publication number: 20230203497
    Abstract: The present disclosure relates to an inhibitor of Dynamin 2 for use in the treatment of centronuclear myopathies. The present disclosure relates to pharmaceutical compositions containing Dynamin 2 inhibitor and to their use for the treatment of centronuclear myopathies. It also deals with a method for identifying or screening molecules useful in the treatment of a centronuclear myopathy.
    Type: Application
    Filed: November 9, 2022
    Publication date: June 29, 2023
    Inventors: JOCELYN LAPORTE, BELINDA COWLING, HICHEM TASFAOUT
  • Compositions and method for the treatment of x-linked centronuclear myopathy
    Patent number: 11666628
    Abstract: The present disclosure relates to a BIN1 protein or a BIN1 nucleic acid sequence producing or encoding the same, for a use in the treatment of X-linked centronuclear myopathy. The present invention provides compositions and methods for treatment of X-linked centronuclear myopathy. The present invention relates to a method of delivering the BIN1 polypeptide to subjects with X-linked centronuclear myopathy.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: June 6, 2023
    Assignees: UNIVERSITE DE STRASBOURG, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jocelyn Laporte, Valentina Lionello, Belinda Cowling
  • Dynamin 2 inhibitor for the treatment of centronuclear myopathies
    Patent number: 11499155
    Abstract: The present disclosure relates to an inhibitor of Dynamin 2 for use in the treatment of centronuclear myopathies. The present disclosure relates to pharmaceutical compositions containing Dynamin 2 inhibitor and to their use for the treatment of centronuclear myopathies. It also deals with a method for identifying or screening molecules useful in the treatment of a centronuclear myopathy.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: November 15, 2022
    Assignees: UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Jocelyn Laporte, Belinda Cowling, Hichem Tasfaout
  • AMPHIPHYSIN / BIN1 FOR THE TREATMENT OF AUTOSOMAL DOMINANT CENTRONUCLEAR MYOPATHY
    Publication number: 20220184176
    Abstract: The present disclosure relates to a BIN1 protein or a BIN1 nucleic acid sequence producing or encoding the same, for a use in the treatment of Autosomal dominant centronuclear myopathy. The present invention provides compositions and methods for treatment of Autosomal dominant centronuclear myopathy. The present invention relates to a method of delivering the BIN1 polypeptide to subjects with Autosomal Dominant Centronuclear Myopathy.
    Type: Application
    Filed: March 20, 2020
    Publication date: June 16, 2022
    Inventors: VALENTINA MARIA LIONELLO, JOCELYN LAPORTE
  • DYNAMIN 2 INHIBITOR FOR THE TREATMENT OF DUCHENNE'S MUSCULAR DYSTROPHY
    Publication number: 20210130447
    Abstract: The present disclosure relates to an inhibitor of Dynamin 2 or composition comprising the same for use in the treatment of Duchenne's muscular dystrophy.
    Type: Application
    Filed: October 30, 2020
    Publication date: May 6, 2021
    Inventors: JOCELYN LAPORTE, BELINDA COWLING
  • COMPOSITIONS AND METHOD FOR THE TREATMENT OF X-LINKED CENTRONUCLEAR MYOPATHY
    Publication number: 20200405804
    Abstract: The present disclosure relates to a BIN1 protein or a BIN1 nucleic acid sequence producing or encoding the same, for a use in the treatment of X-linked centronuclear myopathy. The present invention provides compositions and methods for treatment of X-linked centronuclear myopathy. The present invention relates to a method of delivering the BIN1 polypeptide to subjects with X-linked centronuclear myopathy.
    Type: Application
    Filed: November 12, 2018
    Publication date: December 31, 2020
    Inventors: JOCELYN LAPORTE, VALENTINA LIONELLO, BELINDA COWLING
  • Dynamin 2 inhibitor for the treatment of Duchenne's muscular dystrophy
    Patent number: 10822400
    Abstract: The present disclosure relates to an inhibitor of Dynamin 2 or composition comprising the same for use in the treatment of Duchenne's muscular dystrophy.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: November 3, 2020
    Assignees: UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Jocelyn Laporte, Belinda Cowling
  • DYNAMIN 2 INHIBITOR FOR THE TREATMENT OF CENTRONUCLEAR MYOPATHIES
    Publication number: 20200308589
    Abstract: The present disclosure relates to an inhibitor of Dynamin 2 for use in the treatment of centronuclear myopathies. The present disclosure relates to pharmaceutical compositions containing Dynamin 2 inhibitor and to their use for the treatment of centronuclear myopathies. It also deals with a method for identifying or screening molecules useful in the treatment of a centronuclear myopathy.
    Type: Application
    Filed: May 6, 2020
    Publication date: October 1, 2020
    Inventors: JOCELYN LAPORTE, BELINDA COWLING, HICHEM TASFAOUT
  • MTMR2-S POLYPEPTIDE FOR USE IN THE TREATMENT OF MYOPATHIES
    Publication number: 20200215168
    Abstract: The present disclosure relates to a MTMR2-S polypeptide, or a nucleic acid sequence producing or encoding said MTMR2-S polypeptide, for a use in the treatment of a disease or disorder associated with MTM1 mutation or deficiency. The present invention provides compositions and methods for treatment of myopathy or diseases or disorders associated with MTM1 mutation or deficiency, in a subject in need thereof. The present invention relates to a method of delivering the MTMR2-S polypeptide to subjects in need of improved muscle function, such as subjects with centronuclear myopathies.
    Type: Application
    Filed: July 3, 2018
    Publication date: July 9, 2020
    Inventors: JOCELYN LAPORTE, BELINDA COWLING, MATTHIEU RAESS, SYLVIE FRIANT-MICHEL, DIMITRI BERTAZZI
  • Dynamin 2 inhibitor for the treatment of centronuclear myopathies
    Patent number: 10647986
    Abstract: The present disclosure relates to an inhibitor of Dynamin 2 for use in the treatment of centronuclear myopathies. The present disclosure relates to pharmaceutical compositions containing Dynamin 2 inhibitor and to their use for the treatment of centronuclear myopathies. It also deals with a method for identifying or screening molecules useful in the treatment of a centronuclear myopathy.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: May 12, 2020
    Assignees: UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Jocelyn Laporte, Belinda Cowling, Hichem Tasfaout
  • DYNAMIN 2 INHIBITOR FOR THE TREATMENT OF DUCHENNE'S MUSCULAR DYSTROPHY
    Publication number: 20180142008
    Abstract: The present disclosure relates to an inhibitor of Dynamin 2 or composition comprising the same for use in the treatment of Duchenne's muscular dystrophy.
    Type: Application
    Filed: April 22, 2016
    Publication date: May 24, 2018
    Applicants: UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: JOCELYN LAPORTE, BELINDA COWLING
  • DYNAMIN 2 INHIBITOR FOR THE TREATMENT OF CENTRONUCLEAR MYOPATHIES
    Publication number: 20160264976
    Abstract: The present disclosure relates to an inhibitor of Dynamin 2 for use in the treatment of centronuclear myopathies. The present disclosure relates to pharmaceutical compositions containing Dynamin 2 inhibitor and to their use for the treatment of centronuclear myopathies. It also deals with a method for identifying or screening molecules useful in the treatment of a centronuclear myopathy.
    Type: Application
    Filed: October 20, 2014
    Publication date: September 15, 2016
    Inventors: JOCELYN LAPORTE, BELINDA COWLING, HICHEM TASFAOUT
  • Tyrosine-phosphatase-related protein
    Patent number: 6312688
    Abstract: The present invention relates to a tyrosine-phosphatase-related protein, a DNA which codes for such a protein and a process for producing such a protein. In addition, the invention concerns the use of the DNA and protein and antibodies directed against the protein.
    Type: Grant
    Filed: March 2, 1999
    Date of Patent: November 6, 2001
    Assignees: Deutsches Krebsotorschungszentrum Stiftung des Offentlichen Rechts,, Institut National de la Sante et de la Recherche Medicale
    Inventors: Annemarie Poustka, Petra Kioschis, Jocelyn Laporte, Ling Jia Hu, Jean Louis Mandel, Niklas Dahl